Welcome to our dedicated page for Spyre Therapeutics news (Ticker: $SYRE), a resource for investors and traders seeking the latest updates and insights on Spyre Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Spyre Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Spyre Therapeutics's position in the market.
Spyre Therapeutics, Inc. reported its first-quarter 2024 financial results and provided corporate updates. The company is advancing its anti-α4β7 antibody, SPY001, and anti-TL1A antibody, SPY002, towards first-in-human studies. With $485 million in cash and expected runway until 2027, Spyre is on track to achieve significant milestones in 2024 and beyond.
Spyre Therapeutics, Inc. announced the approval of grants of stock options to 4 non-executive employees as equity inducement awards. These options were granted under the 2018 Equity Inducement Plan with a 10-year term and an exercise price of $33.87 per share. The options will vest over time, subject to continuous service with Spyre.